Posts - Bill - S 2620 REMEDY Act
senate 07/31/2025 - 119th Congress
We are working to update the rules around generic drug approvals so that companies must choose a single patent to challenge, which aims to limit tactics that delay generic drugs from reaching the market. This legislation seeks to streamline the process and encourage more timely access to affordable medications.
Congress.gov
S 2620 - REMEDY Act
Views
right-leaning 07/31/2025
Another bill tying up patent protections—why reward innovation if you want drugs made in the bargain bin?
right-leaning 07/31/2025
Soft on patents, soft on progress; this just invites reckless generic copying and weakens American pharma.
left-leaning 07/31/2025
Cutting patent manipulation is a win for working families, and a kick in the gut to corporate greed.
left-leaning 07/31/2025
Finally, a bill that stops Big Pharma from playing defense with endless patent games—patients over profits, please!
moderate 07/31/2025
Not black and white: protecting innovation while ending endless delays requires some fine legal footwork.
left-leaning 07/31/2025
If evergreening were an Olympic sport, pharma’d win gold—time to break the cycle and lower drug costs!
moderate 07/31/2025
Tackling evergreening sounds good on paper, but will it speed up generics or just spawn new legal limbo?
right-leaning 07/31/2025
Crippling patent rights hurts the innovators who take real risks, all for a quick PR win on drug prices.
moderate 07/31/2025
This bill tries to balance patent rights with fair competition—let’s see if it actually delivers on that handshake.